1. Home
  2. IOVA vs SLRC Comparison

IOVA vs SLRC Comparison

Compare IOVA & SLRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • SLRC
  • Stock Information
  • Founded
  • IOVA 2007
  • SLRC 2007
  • Country
  • IOVA United States
  • SLRC United States
  • Employees
  • IOVA N/A
  • SLRC N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • SLRC Finance/Investors Services
  • Sector
  • IOVA Health Care
  • SLRC Finance
  • Exchange
  • IOVA Nasdaq
  • SLRC Nasdaq
  • Market Cap
  • IOVA 975.1M
  • SLRC 889.2M
  • IPO Year
  • IOVA N/A
  • SLRC 2010
  • Fundamental
  • Price
  • IOVA $2.38
  • SLRC $16.44
  • Analyst Decision
  • IOVA Buy
  • SLRC Hold
  • Analyst Count
  • IOVA 11
  • SLRC 6
  • Target Price
  • IOVA $11.90
  • SLRC $16.13
  • AVG Volume (30 Days)
  • IOVA 11.2M
  • SLRC 163.1K
  • Earning Date
  • IOVA 11-06-2025
  • SLRC 11-05-2025
  • Dividend Yield
  • IOVA N/A
  • SLRC 9.81%
  • EPS Growth
  • IOVA N/A
  • SLRC N/A
  • EPS
  • IOVA N/A
  • SLRC 1.63
  • Revenue
  • IOVA $241,525,000.00
  • SLRC $222,445,000.00
  • Revenue This Year
  • IOVA $67.40
  • SLRC N/A
  • Revenue Next Year
  • IOVA $56.32
  • SLRC $0.38
  • P/E Ratio
  • IOVA N/A
  • SLRC $10.27
  • Revenue Growth
  • IOVA 636.99
  • SLRC N/A
  • 52 Week Low
  • IOVA $1.64
  • SLRC $13.64
  • 52 Week High
  • IOVA $12.51
  • SLRC $17.94
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 49.08
  • SLRC 47.57
  • Support Level
  • IOVA $2.27
  • SLRC $16.55
  • Resistance Level
  • IOVA $2.46
  • SLRC $16.83
  • Average True Range (ATR)
  • IOVA 0.14
  • SLRC 0.19
  • MACD
  • IOVA 0.00
  • SLRC -0.01
  • Stochastic Oscillator
  • IOVA 49.09
  • SLRC 52.44

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About SLRC SLR Investment Corp.

SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.

Share on Social Networks: